contract manufacturing

Latest Headlines

Latest Headlines

Manufacturers' association says pharma contract manufacturing in India growing at 20%

The Indian Drug Manufacturers' Association says the country's pharmaceutical contract manufacturing industry is growing at 20%.

Norway's Weifa bets growth on separate API biz

Norwegian drugmaker Weifa figures its consumer health biz and its contract active pharmaceutical ingredient operations both have a better shot at growth if they go their separate ways. To make that happen, Weifa plans on spinning the API business off into a contract manufacturing operation, with its first contract to make the APIs for Weifa.

New Jersey company investing up to $1M in plant, now offers contract manufacturing

Enteris BioPharma, which was formed in August 2013, will offer contract manufacturing after investing about $1 million into its 32,000-square-foot, FDA-approved manufacturing plant where it makes active pharmaceutical ingredients (APIs) up to commercial scale using microbial expression systems.

India's Piramal says it will snatch up university CDMO for its injectables skills

India's Piramal Enterprises said it was on the cusp of buying a CDMO founded at the University of Kentucky. That comes weeks after Japan's Fujifilm Diosynth Biotechnologies bought half of a vaccine manufacturing specialist from the Texas A&M University System.

Avid Bioservices doubling capacity at its California facility

California-based Peregrine Pharmaceuticals says that contract manufacturing revenue was off in its last quarter but demand remains high for its Avid Bioservices unit, and so like a number of contract manufacturers that target biologics, it is adding capacity.

Grand River opens new finishing facility

Grand River Aseptic Manufacturing (GRAM), a small parenteral contract manufacturing company in Grand Rapids, MI, has opened a new 28,000-square-foot facility for its finishing operations, inspection services and storage, as well as housing a substantially larger lab, Contract Pharma reports.

Cubist issues third recall in 12 months after another CMO quality failing

Cubist is going through a bad patch with outsourced production. The problems began in August 2013, when CMO quality failings prompted Cubist to recall four lots of its injectable antibiotic Cubicin. Having summoned back another lot in April, Cubist has now issued a much larger recall, with about 100 lots affected.

Aptuit putting $1M into cytotoxic capabilities in Scotland

Contract services company Aptuit will invest $1 million in its facility in Glasgow, Scotland, to expand its capacity to manufacture sterile cytotoxic liquid and lyophilized drug products.

Global CMOs tipped to enter Russia as local drug production deadline nears

While geopolitical instability in Eastern Europe would appear to make Russia a risky bet, the size of the market and incoming targets on drug production mean the likes of Abbott Laboratories are still investing. For companies unwilling or unable to strike deals like Abbott's $495 million buyout of Veropharm, a new option is tipped to emerge: CMOs.

FDA sues to halt production of 'unapproved' vaginal gel products

California contract manufacturer Laclede was warned. Now it is being legally stormed. After years of letters, inspections and meetings with the FDA couldn't move the company to seek an NDA for its vaginal gel products, the FDA has sued Laclede to get it to stop making them.